CD274 and lung carcinoma: In the 2023 World Conference on Lung Cancer, CheckMate 227 showed that after 6 years of follow‐up, nivolumab in combination with ipilimumab could improve OS over standard chemotherapy by 3.2 months (HR = 0.73), and the 5‐year OS rates for nivolumab in combination with ipilimumab versus chemotherapy were 24 versus 14% (PD‐L1 ≥ 1%) and 19 versus 7% (PD‐L1 < 1%), respectively [126].